Search

Your search keyword '"soluble urokinase–type plasminogen activator receptor (suPAR)"' showing total 32 results

Search Constraints

Start Over You searched for: Descriptor "soluble urokinase–type plasminogen activator receptor (suPAR)" Remove constraint Descriptor: "soluble urokinase–type plasminogen activator receptor (suPAR)"
32 results on '"soluble urokinase–type plasminogen activator receptor (suPAR)"'

Search Results

1. Circulating miR-10b, soluble urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 as predictors of non-small cell lung cancer progression and treatment response.

2. Soluble urokinase-type plasminogen activator receptor (suPAR) is elevated in caregivers of patients with parkinsonism.

3. suPAR to Risk-Stratify Patients With Malaria.

4. suPAR to Risk-Stratify Patients With Malaria

5. Poder pronóstico de mortalidad a corto plazo del receptor soluble activador del plasminógeno tipo uroquinasa (suPAR) en los pacientes atendidos en urgencias por infección.

6. Soluble urokinase type plasminogen activator receptor (suPAR) and mortality in acute pulmonary embolism.

7. Long term pronostic value of suPAR in chronic heart failure: reclassification of patients with low MAGGIC score.

8. The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine

9. Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes.

10. The clinical value of suPAR in diagnosis and prediction for patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.

11. A Successfully Treated Case of Recurrent Focal Segmental Glomerulosclerosis (FSGS) with Plasmapheresis and High dose Methylprednisolone Pulse Therapy

12. Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction.

13. The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine.

14. Poder pronóstico de mortalidad a corto plazo del receptor soluble activador del plasminógeno tipo uroquinasa (suPAR) en los pacientes atendidos en urgencias por infección

15. Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes

16. Soluble urokinase Plasminogen Activator Receptor (suPAR) as a prognostic biomarker in cardiogenic shock: a prospective observational pilot study

17. Perturbations in podocyte transcriptome and biological pathways induced by FSGS associated circulating factors.

18. The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine

19. Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction

20. Long term pronostic value of suPAR in chronic heart failure: reclassification of patients with low MAGGIC score

21. Serum suPAR levels are modulated by immunosuppressive therapy of minimal change nephrotic syndrome.

22. Circulating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non-Hodgkin's lymphoma.

23. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.

24. The Diagnostic and Prognostic Value of suPAR in Patients with Sepsis: A Systematic Review and Meta-Analysis

25. Associations of Plasma Biomarkers of Inflammation, Fibrosis, and Kidney Tubular Injury With Progression of Diabetic Kidney Disease: A Cohort Study.

26. The clinical value of suPAR in diagnosis and prediction for patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis

27. Fetal Renal Echogenicity Associated with Maternal Focal Segmental Glomerulosclerosis: The Effect of Transplacental Transmission of Permeability Factor suPAR

28. Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte β3 Integrin.

29. New Cardiovascular Biomarkers in Ischemic Heart Disease—GDF-15, A Probable Predictor for Ejection Fraction.

30. suPAR as a prognostic biomarker in sepsis

31. Fetal Renal Echogenicity Associated with Maternal Focal Segmental Glomerulosclerosis: The Effect of Transplacental Transmission of Permeability Factor suPAR.

32. Soluble urokinase-type Plasminogen Activator Receptor (suPAR) as an independent factor predicting worse prognosis and extra bone marrow involvement in multiple myeloma patients

Catalog

Books, media, physical & digital resources